Bio-Techne Corp.

TECH14 Dec 2024
Healthcare
$76.58
-0.01 (-1.29%)
Lowest Today
$74.41
Highest Today
$76.58
Today’s Open
$76.58
Prev. Close
$76.68
52 Week High
$85.39
52 Week Low
$60.97
To Invest in Bio-Techne Corp.

Bio-Techne Corp.

Healthcare
TECH14 Dec 2024
-0.01 (-1.29%)
1M
3M
6M
1Y
5Y
Low
$74.41
Day’s Range
High
$76.58
74.41
52 Week Low
$60.97
52-Week Range
52 Week High
$85.39
60.97
1 Day
-
1 Week
-2.35%
1 month return
+4.25%
3 month return
+1.11%
6 month return
-0.32%
1 Year return
+0.71%
3 Years return
-34.56%
5 Years return
+38.32%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
11.53
BlackRock Inc
9.43
T. Rowe Price Associates, Inc.
5.93
State Street Corp
4.03
US Small-Cap Growth II Equity Comp
3.67
T. Rowe Price New Horizons
3.67
Vanguard Total Stock Mkt Idx Inv
3.17

Market Status

Fundamentals
Market Cap
12204.47 mln
PB Ratio
5.71
PE Ratio
80.72
Enterprise Value
12415.86 mln
Total Assets
2703.87 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Organisation
Bio-Techne Corp.
Employees
3100
Industry
Biotechnology
CEO
Mr. Kim  Kelderman
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities